Drug Trial Radar · NCT04309916
Study to Evaluate the Efficacy and Safety of Tegoprazan in ERD Patients With Nighttime Heartburn and Sleep Disturbance
Last checked: Nov 20, 2026Latest source record: Feb 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
May 22, 2020
Primary completion
Nov 30, 2021
Study completion Nov 30, 2021
Sponsor
- Lead sponsor
- HK inno.N CorporationIndustry
- Sponsor type
- Industry
- First posted
- Mar 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to compare the nighttime heartburn and sleep disturbance improvement effect of Tegoprazan 50mg and Eomeprazole 40mg in patients with ERD patients.
Conditions
- Erosive Reflux Disease
Interventions
TegoprazanDrug
Tegoprazan 50mg tablet
EsomeprazoleDrug
Esomeprazole 40mg tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first nighttime heartburn-free interval (days))Time frame: 2 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Severance Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.